Aprotinin (Trasylol) Down But Not Totally Out

Courtesy MedPage Today Surgery  Thu, 05/15/2008 - 08:02

ROCKVILLE, Md. -- The hemostasis drug aprotinin (Trasylol) will remain available to U.S. physicians under an investigational protocol, at least until the FDA sorts out the causes of excess deaths seen with the drug in a large randomized trial, the agency said.

Tags:

 

More related items

Faster, Simpler Seizure Rx More Effective, Too...
(MedPage Today) -- Intramuscular midazolam proved significantly better at ending seizures outside the hospital environment than intravenous lorazepam, a randomized trial showed.

Amiodarone After Lung Surgery Cuts Afib (CME/CE)
FT. LAUDERDALE (MedPage Today) -- Postoperative administration of amiodarone after lung cancer resection significantly reduced the risk of atrial fibrillation in a randomized trial.

Balloon Better Emboli Guard in Carotid Stenting...
(MedPage Today) -- Occluding the proximal carotid artery with a balloon may confer better protection against cerebral embolization than a filter device during carotid stenting, a randomized...

The Unwritten Rules of Friendship: Simple Strategies...
"Nobody likes me!" is a complaint that parents hear all too often, and few utterances make them feel more helpless. Now help is at hand: This practical and compassionate guidebook enables...

Burt's Bees Free Head to Toe Starter Kit


 

Post new comment

The content of this field is kept private and will not be shown publicly.
health-fitness.marc8.com